About Us

According to the American Cancer Society approximately 1.5 million new cases of cancer are diagnosed each year in the U.S.  Today, there are over 11 million Americans living with cancer.  Virtually all cancers are either aggressive at the onset or become aggressive over time.

Aggressive cancers occurring at the onset are generally refractory to conventional chemotherapy and often non-operable.  They are invasive and characterized by rapid proliferation.  Examples of such cancers include small-cell lung cancer, pancreatic cancer, kidney cancer, and squamous-cell carcinomas.  Cancers which become aggressive following one or more rounds of therapy are generally referred to as metastatic or multidrug resistant.  These types of cancer are initially operable solid tumors and generally respond to chemotherapy.  However, when they recur they are characteristically aggressive, more proliferative and multidrug resistant.

Sunshine Biopharma is committed to developing novel therapies for the treatment of various forms of aggressive cancer types.  Our initial drug candidate, Adva-27a, is a small molecule that has proven effective against different types of multidrug resistant cancer cell lines including breast cancer (MCF-7/MDR), small-cell lung cancer (H69AR), uterine carcinoma (MES-SA/Dx5) and pancreatic cancer (Panc-1).

Read more…
Lead Compound
Publications